Key clinical point: The response to standard treatments is disappointing in patients with KRASG12C-mutant metastatic colorectal cancer (mCRC), highlighting an urgent need for target therapies with selective KRASG12C inhibitors.
Major finding: The overall response rate was 38.7%, and the median progression-free survival and overall survival were 9 months (95% CI 7.5-10.5) and 21 months (95% CI 17.4-24.6), respectively. Only 62% and 36% of the patients who progressed received a second- and third-line treatment, respectively, with limited clinical benefits.
Study details : Findings are from a retrospective analysis of 111 patients with unresectable mCRC harboring KRASG12C mutation who received first-line doublet or triplet chemotherapy .
Disclosures: The study did not declare any source of funding. Some authors declared serving as consultants, advisors, or speakers for or receiving personal fees, travel and accommodation expenses, or research grants from various sources.
Source: Ciardiello D et al. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: Findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open. 2022;7(5):100567 (Aug 19). Doi: 10.1016/j.esmoop.2022.100567